HDAC inhibitors and cardiac safety.
Molife
Rhoda
R
Fong
Peter
P
Scurr
Michelle
M
Judson
Ian
I
Kaye
Stan
S
de Bono
Johann
J
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D047630:Depsipeptides / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D004562:Electrocardiography / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006331:Heart Diseases / Q000139:chemically induced* / Q000473:pathology; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D020714:Maximum Tolerated Dose; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D012306:Risk; D013449:Sulfonamides; D016171:Torsades de Pointes / Q000139:chemically induced
D000970:Antineoplastic Agents; D047630:Depsipeptides; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C477361:LAQ824; D013449:Sulfonamides; C087123:romidepsin; C487081:belinostat